Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Savara Inc. (SVRA)
USD5.50
+0.12 (+2.23%)
US NASDAQ Healthcare Biotechnology
Address
Building III 78746
Langhorne, TX, US
Langhorne, TX, US
CEO
Matthew Pauls
Website
savarapharma.com
IPO
2017-04-28
CIK 1160308 ISIN US8051111016
Description
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Mast | MSTX | 2017-02-10 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.50
+0.12 (+2.23%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.27
Float Shares
105.15M
Free Float %
51.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.78% | -3.79% | -10.25% | -12.86% | +23.30% | -15.75% | +68.21% | +155.28% | +229.87% | -42.01% | -42.01% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
5.50
Low
10.00
+81.8%
Consensus
10.00
+81.8%
Median
10.00
+81.8%
High
10.00
+81.8%
DCF (Levered)
0.01
-99.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
10.00
+81.8%
|
| Last Year | 6 |
9.50
+72.7%
|
| All Time | 11 |
7.45
+35.5%
|
Quality scores
Altman Z-Score
8.68
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-10.4% Q1'26: -25.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+12.2% Q1'26: +17.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.24× Q1'26: -0.19× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2018 actual |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 6 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
400.0K
est: 22.5K (+1,677.8%)
|
—
est: 150.0K (-100.0%)
|
257.0K
est: 267.3K (-3.8%)
|
—
|
—
est: 1.39M (-100.0%)
|
11.00M
3.12M – 15.14M
+688.7% YoY
|
72.97M
60.99M – 84.94M
+563.4% YoY
|
166.50M
116.97M – 208.72M
+128.2% YoY
|
300.50M
211.12M – 376.71M
+80.5% YoY
|
430.12M
302.18M – 539.20M
+43.1% YoY
|
| EBITDA |
-10.48M
est: 13.5K (-77,744.4%)
|
-69.50M
est: 90.0K (-77,323.3%)
|
-45.85M
est: 160.4K (-28,694.9%)
|
-102.27M
|
-123.46M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-10.83M
est: 13.5K (-80,307.4%)
|
-70.03M
est: 90.0K (-77,907.8%)
|
-46.11M
est: 160.4K (-28,854.0%)
|
-102.40M
|
-123.55M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-10.92M
est: -2.77B (+99.6%)
|
-61.52M
est: -385.15M (+84.0%)
|
-49.62M
est: -123.21M (+59.7%)
|
-95.88M
est: -91.42M (-4.9%)
|
-118.84M
est: -118.84M (+0.0%)
|
-112.03M
-122.66M – -95.17M
+5.7% YoY
|
-61.40M
-86.80M – -49.60M
+45.2% YoY
|
14.04M
-4.45M – 44.48M
+122.9% YoY
|
96.18M
58.99M – 127.89M
+585.0% YoY
|
166.79M
102.30M – 221.78M
+73.4% YoY
|
| SGA |
2.82M
est: 227.5K (+1,139.6%)
|
10.65M
est: 1.52M (+602.5%)
|
11.96M
est: 2.70M (+342.8%)
|
25.04M
|
42.06M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.27
est: -14.00 (+76.6%)
|
-1.85
est: -1.94 (+4.8%)
|
-0.84
est: -0.62 (-35.1%)
|
-0.48
est: -0.46 (-4.1%)
|
-0.53
est: -0.61 (+13.0%)
|
-0.49
-0.55 – -0.43
+20.4% YoY
|
-0.31
-0.39 – -0.22
+36.8% YoY
|
0.05
-0.02 – 0.20
+117.6% YoY
|
0.43
0.27 – 0.58
+700.9% YoY
|
0.75
0.46 – 1.00
+73.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-106.89M
OE per share TTM
-0.47
Owner's Yield
-8.31%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
454.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
54
Total invested
136.08M
Insider transactions (90d)
0
Beneficial owners (>5%)
38
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chen Yu | 10.00M | 7.40% | — | 10.00M | — | 10.00M | IN | United States America | 2023-07-25 | ↗ |
| 2 | TCG Crossover Fund I, L.P. | 10.00M | 7.40% | — | 10.00M | — | 10.00M | PN | United States America | 2023-07-25 | ↗ |
| 3 | TCG Crossover GP I, LLC | 10.00M | 7.40% | — | 10.00M | — | 10.00M | OO | United States America | 2023-07-25 | ↗ |
| 4 | (1) BlackRock, Inc. | 9.40M | 5.70% | — | — | 9.40M | — | HC | Delaware | 2024-11-08 | ↗ |
| 5 | James N. Topper | 8.66M | 5.00% | — | 8.66M | — | 8.66M | IN | Delaware | 2024-11-27 | ↗ |
| 6 | Patrick J. Heron | 8.66M | 5.00% | — | 8.66M | — | 8.66M | IN | Delaware | 2024-11-27 | ↗ |
| 7 | Wellington Group Holdings LLP | 8.62M | 5.24% | — | 7.35M | — | — | HC | Massachusetts | 2024-11-08 | ↗ |
| 8 | Wellington Investment Advisors Holdings LLP | 8.62M | 5.24% | — | 7.35M | — | — | HC | Massachusetts | 2024-11-08 | ↗ |
| 9 | Wellington Management Group LLP | 8.62M | 5.24% | — | 7.35M | — | — | HC | Massachusetts | 2024-11-08 | ↗ |
| 10 | Wellington Management Company LLP | 8.41M | 5.11% | — | 7.35M | — | — | IA | Massachusetts | 2024-11-08 | ↗ |
| 11 | Albert Cha | 7.04M | 4.10% | — | 7.04M | — | 7.04M | IN | Delaware | 2024-11-27 | ↗ |
| 12 | James Brush | 7.04M | 4.10% | — | 7.04M | — | 7.04M | IN | Delaware | 2024-11-27 | ↗ |
| 13 | Bruce S. Kovner | 6.90M | 6.10% | — | 6.90M | — | 6.90M | IN | Delaware | 2022-02-14 | ↗ |
| 14 | CDK Associates, L.L.C. | 6.48M | 5.70% | — | 6.48M | — | 6.48M | OO | Delaware | 2022-02-14 | ↗ |
| 15 | Koh, Bong | 6.19M | 5.40% | — | 6.19M | — | — | IN | Delaware | 2022-11-14 | ↗ |
| 16 | Shah, Nimish | 6.19M | 5.40% | — | 6.19M | — | — | IN | Delaware | 2022-11-14 | ↗ |
| 17 | VHCP Co-Investment Holdings II, LLC | 6.19M | 5.40% | — | 6.19M | — | — | OO | Delaware | 2022-11-14 | ↗ |
| 18 | VHCP Co-Investment Holdings III, LLC | 6.19M | 5.40% | — | 6.19M | — | — | OO | Delaware | 2022-11-14 | ↗ |
| 19 | VHCP Management EG, LLC | 6.19M | 5.40% | — | 6.19M | — | 6.19M | OO | Delaware | 2022-11-14 | ↗ |
| 20 | VHCP Management II, LLC | 6.19M | 5.40% | — | 6.19M | — | 6.19M | OO | Delaware | 2022-11-14 | ↗ |
| 21 | VHCP Management III, LLC | 6.19M | 5.40% | — | 6.19M | — | 6.19M | OO | Delaware | 2022-11-14 | ↗ |
| 22 | Venrock Healthcare Capital Partners EG, L.P. | 6.19M | 5.40% | — | 6.19M | — | 6.19M | PN | Delaware | 2022-11-14 | ↗ |
| 23 | Venrock Healthcare Capital Partners II, L.P. | 6.19M | 5.40% | — | 6.19M | — | — | PN | Delaware | 2022-11-14 | ↗ |
| 24 | Venrock Healthcare Capital Partners III, L.P. | 6.19M | 5.40% | — | 6.19M | — | — | PN | Delaware | 2022-11-14 | ↗ |
| 25 | FHMLSP, L.L.C. | 4.74M | 2.80% | — | 4.74M | — | 4.74M | OO | Delaware | 2024-11-27 | ↗ |
| 26 | FHMLSP, L.P. | 4.74M | 2.80% | — | 4.74M | — | 4.74M | PN | Delaware | 2024-11-27 | ↗ |
| 27 | Frazier Life Sciences Public Fund, L.P. | 4.74M | 2.80% | — | 4.74M | — | 4.74M | PN | Delaware | 2024-11-27 | ↗ |
| 28 | EcoR1 Capital, LLC | 3.04M | 11.00% | — | 3.04M | — | 3.04M | OO | Delaware | 2022-02-14 | ↗ |
| 29 | FHMLSP Overage, L.L.C. | 2.30M | 1.30% | — | 2.30M | — | 2.30M | OO | Delaware | 2024-11-27 | ↗ |
| 30 | FHMLSP Overage, L.P. | 2.30M | 1.30% | — | 2.30M | — | 2.30M | PN | Delaware | 2024-11-27 | ↗ |
| 31 | Frazier Life Sciences Public Overage Fund, L.P. | 2.30M | 1.30% | — | 2.30M | — | 2.30M | PN | Delaware | 2024-11-27 | ↗ |
| 32 | Daniel Estes | 1.37M | 0.80% | — | 1.37M | — | 1.37M | IN | Delaware | 2024-11-27 | ↗ |
| 33 | FHMLS XI, L.L.C. | 1.37M | 0.80% | — | 1.37M | — | 1.37M | OO | Delaware | 2024-11-27 | ↗ |
| 34 | FHMLS XI, L.P. | 1.37M | 0.80% | — | 1.37M | — | 1.37M | PN | Delaware | 2024-11-27 | ↗ |
| 35 | Frazier Life Sciences XI, L.P. | 1.37M | 0.80% | — | 1.37M | — | 1.37M | PN | Delaware | 2024-11-27 | ↗ |
| 36 | FHMLS X, L.L.C. | 249.5K | 0.10% | — | 249.5K | — | 249.5K | OO | Delaware | 2024-11-27 | ↗ |
| 37 | FHMLS X, L.P. | 249.5K | 0.10% | — | 249.5K | — | 249.5K | PN | Delaware | 2024-11-27 | ↗ |
| 38 | Frazier Life Sciences X, L.P. | 249.5K | 0.10% | — | 249.5K | — | 249.5K | PN | Delaware | 2024-11-27 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
54
-98 vs prev Q
New positions
22
Closed positions
115
Increased
37
Reduced
13
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 605.3K +605.3K (+100.0%) | 3.65B +3.6B (+100.0%) | 0.28% +0.280 pp | 3.53% +3.532 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 2 | NEA MANAGEMENT COMPANY, LLC | 24.47M +— (+0.0%) | 147.56M +60.2M (+68.9%) | 11.31% -0.002 pp | 7.52% +2.730 pp | USD2.10 +187.1% | 20 qtrs — |
| 3 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 17.60M +— (+0.0%) | 106.13M +43.3M (+68.9%) | 8.13% -0.001 pp | 8.13% +3.958 pp | USD3.20 +88.4% | 25 qtrs — |
| 4 | VR ADVISER, LLC | 13.74M +1.1M (+8.4%) | 82.85M +37.6M (+83.0%) | 6.35% +0.489 pp | 4.09% +1.545 pp | USD3.04 +98.4% | 4 qtrs — |
| 5 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 13.57M +5.6M (+70.4%) | 81.82M +53.4M (+187.8%) | 6.27% +2.589 pp | 1.04% +0.611 pp | USD4.85 +24.3% | 6 qtrs — |
| 6 | TCG CROSSOVER MANAGEMENT, LLC | 12.36M +— (+0.0%) | 74.54M +30.4M (+68.9%) | 5.71% -0.001 pp | 2.47% +0.296 pp | USD3.94 +53.0% | 10 qtrs — |
| 7 | BLACKROCK, INC. | 11.10M +2.6M (+31.4%) | 66.92M +36.8M (+121.9%) | 5.13% +1.223 pp | 0.00% +0.001 pp | USD4.61 +30.8% | 6 qtrs — |
| 8 | VANGUARD GROUP INC | 10.04M +1.7M (+20.8%) | 60.55M +30.9M (+104.0%) | 4.64% +0.798 pp | 0.00% +0.000 pp | USD4.26 +41.5% | 35 qtrs — |
| 9 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 9.86M -1.6M (-14.0%) | 59.47M +18.5M (+45.3%) | 4.56% -0.740 pp | 1.60% +0.371 pp | USD3.81 +58.3% | 10 qtrs — |
| 10 | POLAR CAPITAL HOLDINGS PLC | 8.31M +8.3M (+100.0%) | 50.09M +50.1M (+100.0%) | 3.84% +3.837 pp | 0.19% +0.194 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 11 | NANTAHALA CAPITAL MANAGEMENT, LLC | 7.34M -1.4M (-16.3%) | 44.29M +13.0M (+41.4%) | 3.39% -0.662 pp | 1.46% +0.376 pp | USD3.90 +54.6% | 10 qtrs — |
| 12 | RTW INVESTMENTS, LP | 5.95M +6.0M (+100.0%) | 35.89M +35.9M (+100.0%) | 2.75% +2.750 pp | 0.36% +0.360 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 13 | MARSHALL WACE, LLP | 4.56M +4.6M (+100.0%) | 27.50M +27.5M (+100.0%) | 2.11% +2.107 pp | 0.03% +0.025 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 14 | STATE STREET CORP | 4.33M +2.0M (+83.6%) | 26.13M +17.7M (+210.1%) | 2.00% +0.911 pp | 0.00% +0.001 pp | USD5.07 +18.9% | 33 qtrs — |
| 15 | WOODLINE PARTNERS LP | 4.24M +4.0M (+1,689.3%) | 25.60M +24.7M (+2,922.3%) | 1.96% +1.851 pp | 0.10% +0.095 pp | USD5.91 +2.0% | 6 qtrs — |
| 16 | EMERALD ADVISERS, LLC | 3.50M -33.8K (-1.0%) | 21.08M +8.5M (+67.3%) | 1.61% -0.016 pp | 0.65% +0.246 pp | USD2.91 +107.2% | 5 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 3.42M +622.1K (+22.3%) | 20.61M +10.6M (+106.5%) | 1.58% +0.287 pp | 0.00% +0.001 pp | USD4.31 +39.9% | 35 qtrs — |
| 18 | ROSALIND ADVISORS, INC. | 3.40M -596.3K (-14.9%) | 20.52M +6.2M (+43.7%) | 1.57% -0.276 pp | 7.21% +2.333 pp | USD3.24 +86.1% | 5 qtrs — |
| 19 | AFFINITY ASSET ADVISORS, LLC | 2.80M +1.3M (+86.5%) | 16.87M +11.5M (+215.0%) | 1.29% +0.599 pp | 0.96% +0.495 pp | USD4.48 +34.6% | 10 qtrs — |
| 20 | WELLINGTON MANAGEMENT GROUP LLP | 2.67M +30.9K (+1.2%) | 16.13M +6.7M (+70.9%) | 1.24% +0.014 pp | 0.00% +0.001 pp | USD4.61 +30.8% | 9 qtrs — |
| 21 | PERCEPTIVE ADVISORS LLC | 2.40M +2.4M (+100.0%) | 14.47M +14.5M (+100.0%) | 1.11% +1.109 pp | 0.26% +0.258 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 22 | EMERALD MUTUAL FUND ADVISERS TRUST | 2.40M +245.1K (+11.4%) | 14.45M +6.8M (+88.2%) | 1.11% +0.113 pp | 0.70% +0.307 pp | USD3.24 +86.1% | 5 qtrs — |
| 23 | MORGAN STANLEY | 2.34M +420.1K (+21.9%) | 14.10M +7.3M (+105.9%) | 1.08% +0.194 pp | 0.00% +0.000 pp | USD3.99 +51.1% | 35 qtrs — |
| 24 | NAN FUNG TRINITY (HK) LTD | 1.69M +1.7M (+100.0%) | 10.18M +10.2M (+100.0%) | 0.78% +0.780 pp | 0.81% +0.807 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 25 | D. E. SHAW & CO., INC. | 1.67M +1.3M (+348.7%) | 10.07M +8.7M (+657.9%) | 0.77% +0.599 pp | 0.01% +0.005 pp | USD5.46 +10.4% | 6 qtrs — |
| 26 | VESTAL POINT CAPITAL, LP | 1.61M -2.4M (-60.0%) | 9.68M -4.6M (-32.4%) | 0.74% -1.113 pp | 0.33% -0.318 pp | USD4.16 +45.0% | 7 qtrs — |
| 27 | ADAR1 CAPITAL MANAGEMENT, LLC | 1.41M -582.8K (-29.3%) | 8.47M +1.4M (+19.4%) | 0.65% -0.269 pp | 0.62% -0.044 pp | USD2.86 +110.8% | 8 qtrs — |
| 28 | LONGAEVA PARTNERS L.P. | 1.25M +1.2M (+100.0%) | 7.51M +7.5M (+100.0%) | 0.58% +0.576 pp | 0.63% +0.630 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 29 | SPHERA FUNDS MANAGEMENT LTD. | 1.18M -172.2K (-12.8%) | 7.10M +2.3M (+47.4%) | 0.54% -0.080 pp | 1.37% +0.357 pp | USD3.71 +62.5% | 7 qtrs — |
| 30 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.16M +197.9K (+20.5%) | 7.00M +3.6M (+103.6%) | 0.54% +0.091 pp | 0.00% +0.001 pp | USD4.34 +38.9% | 31 qtrs — |
| 31 | NORTHERN TRUST CORP | 1.08M +130.9K (+13.8%) | 6.50M +3.1M (+92.3%) | 0.50% +0.060 pp | 0.00% +0.000 pp | USD4.29 +40.6% | 33 qtrs — |
| 32 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 1.06M +1.1M (+100.0%) | 6.40M +6.4M (+100.0%) | 0.49% +0.490 pp | 0.01% +0.007 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 33 | SIREN, L.L.C. | 1.00M +1.0M (+100.0%) | 6.03M +6.0M (+100.0%) | 0.46% +0.462 pp | 0.18% +0.180 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 34 | SUPERSTRING CAPITAL MANAGEMENT LP | 995.4K -313.9K (-24.0%) | 6.00M +1.3M (+28.4%) | 0.46% -0.145 pp | 3.21% -1.391 pp | USD3.21 +87.9% | 9 qtrs — |
| 35 | SWEDBANK AB | 850.0K +300.0K (+54.5%) | 5.13M +3.2M (+161.0%) | 0.39% +0.139 pp | 0.01% +0.003 pp | USD4.44 +35.8% | 2 qtrs — |
| 36 | DEUTSCHE BANK AG\ | 824.7K -26.3K (-3.1%) | 4.97M +1.9M (+63.7%) | 0.38% -0.012 pp | 0.00% +0.001 pp | USD4.62 +30.5% | 10 qtrs — |
| 37 | VOYA INVESTMENT MANAGEMENT LLC | 751.3K -105.3K (-12.3%) | 4.53M +1.5M (+48.1%) | 0.35% -0.049 pp | 0.00% +0.001 pp | USD2.55 +136.5% | 11 qtrs — |
| 38 | INVESCO LTD. | 688.6K +517.3K (+302.1%) | 4.15M +3.5M (+579.1%) | 0.32% +0.239 pp | 0.00% +0.001 pp | USD5.34 +12.9% | 11 qtrs — |
| 39 | F/M INVESTMENTS LLC | 678.8K +245.1K (+56.5%) | 4.09M +2.5M (+164.4%) | 0.31% +0.113 pp | 0.16% +0.096 pp | USD4.06 +48.5% | 5 qtrs — |
| 40 | SIO CAPITAL MANAGEMENT, LLC | 613.9K -113.0K (-15.5%) | 3.70M +1.1M (+42.7%) | 0.28% -0.052 pp | 0.58% -0.074 pp | USD2.77 +117.7% | 5 qtrs — |
| 41 | JANE STREET GROUP, LLC | 584.3K -21.3K (-3.5%) | 3.52M +1.4M (+63.0%) | 0.27% -0.010 pp | 0.00% +0.000 pp | USD3.57 +68.9% | 2 qtrs — |
| 42 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 543.8K +522.4K (+2,445.2%) | 3.28M +3.2M (+4,199.1%) | 0.25% +0.241 pp | 0.00% +0.000 pp | USD5.92 +1.9% | 29 qtrs — |
| 43 | MILLENNIUM MANAGEMENT LLC | 535.0K -309.2K (-36.6%) | 3.23M +212.1K (+7.0%) | 0.25% -0.143 pp | 0.00% +0.000 pp | USD3.57 +68.9% | 9 qtrs — |
| 44 | GOLDMAN SACHS GROUP INC | 516.6K -145.6K (-22.0%) | 3.12M +750.9K (+31.8%) | 0.24% -0.067 pp | 0.00% +0.000 pp | USD3.80 +58.7% | 33 qtrs — |
| 45 | BANK OF AMERICA CORP /DE/ | 423.6K +303.6K (+253.0%) | 2.55M +2.1M (+496.3%) | 0.20% +0.140 pp | 0.00% +0.000 pp | USD5.43 +11.0% | 14 qtrs — |
| 46 | SUMMITTX CAPITAL, L.P. | 373.0K +373.0K (+100.0%) | 2.25M +2.2M (+100.0%) | 0.17% +0.172 pp | 0.07% +0.068 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 47 | RENAISSANCE TECHNOLOGIES LLC | 332.1K +72.0K (+27.7%) | 2.00M +1.1M (+115.7%) | 0.15% +0.033 pp | 0.00% +0.002 pp | USD4.10 +47.1% | 2 qtrs — |
| 48 | BANK OF NEW YORK MELLON CORP | 312.9K +39.5K (+14.5%) | 1.89M +910.7K (+93.3%) | 0.14% +0.018 pp | 0.00% +0.000 pp | USD3.62 +66.6% | 15 qtrs — |
| 49 | BARCLAYS PLC | 306.9K +75.9K (+32.9%) | 1.85M +871.4K (+89.0%) | 0.14% +0.035 pp | 0.00% +0.000 pp | USD4.15 +45.3% | 12 qtrs — |
| 50 | SOFINNOVA INVESTMENTS, INC. | 304.8K -2.1M (-87.4%) | 1.84M -6.8M (-78.8%) | 0.14% -0.981 pp | 0.08% -0.395 pp | USD4.60 +31.1% | 11 qtrs — |
| 51 | NUVEEN, LLC | 272.6K +35.8K (+15.1%) | 1.64M +798.3K (+94.4%) | 0.13% +0.017 pp | 0.00% +0.000 pp | USD3.20 +88.4% | 4 qtrs — |
| 52 | UBS GROUP AG | 202.9K -492.9K (-70.8%) | 1.22M -1.3M (-50.7%) | 0.09% -0.228 pp | 0.00% 0.000 pp | USD3.56 +69.4% | 34 qtrs — |
| 53 | BALYASNY ASSET MANAGEMENT L.P. | 188.2K +188.2K (+100.0%) | 1.13M +1.1M (+100.0%) | 0.09% +0.087 pp | 0.00% +0.001 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 54 | EVERSEPT PARTNERS, LP | 170.2K +170.2K (+100.0%) | 1.03M +1.0M (+100.0%) | 0.08% +0.079 pp | 0.05% +0.052 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 55 | DIMENSIONAL FUND ADVISORS LP | 170.1K -530.5K (-75.7%) | 1.03M -1.5M (-59.0%) | 0.08% -0.245 pp | 0.00% 0.000 pp | USD2.46 +145.1% | 33 qtrs — |
| 56 | WELLS FARGO & COMPANY/MN | 167.6K +83.6K (+99.4%) | 1.01M +710.7K (+236.7%) | 0.08% +0.039 pp | 0.00% +0.000 pp | USD4.68 +28.8% | 33 qtrs — |
| 57 | RHUMBLINE ADVISERS | 152.8K -4.8K (-3.0%) | 921.2K +358.7K (+63.8%) | 0.07% -0.002 pp | 0.00% +0.000 pp | USD3.26 +85.0% | 11 qtrs — |
| 58 | WALLEYE CAPITAL LLC | 150.1K +59.1K (+64.9%) | 905.0K +580.1K (+178.5%) | 0.07% +0.027 pp | 0.00% +0.002 pp | USD4.54 +32.8% | 4 qtrs — |
| 59 | GSA CAPITAL PARTNERS LLP | 140.8K -231.7K (-62.2%) | 849.0K -481.0K (-36.2%) | 0.07% -0.107 pp | 0.07% -0.038 pp | USD2.34 +157.7% | 4 qtrs — |
| 60 | ALLIANCEBERNSTEIN L.P. | 127.0K +8.3K (+6.9%) | 766.1K +342.0K (+80.6%) | 0.06% +0.004 pp | 0.00% +0.000 pp | USD4.00 +50.8% | 11 qtrs — |
| 61 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 90.0K -20.0K (-18.2%) | 549.9K +157.2K (+40.0%) | 0.04% -0.009 pp | 0.00% +0.000 pp | USD2.77 +117.7% | 4 qtrs — |
| 62 | RAFFERTY ASSET MANAGEMENT, LLC | 89.9K +89.9K (+100.0%) | 541.8K +541.8K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.002 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 63 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 86.2K +86.2K (+100.0%) | 519.5K +519.5K (+100.0%) | 0.04% +0.040 pp | 0.00% +0.002 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 64 | CRESSET ASSET MANAGEMENT, LLC | 83.3K +83.3K (+100.0%) | 502.5K +502.5K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.002 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 65 | AQUATIC CAPITAL MANAGEMENT LLC | 83.1K +83.1K (+100.0%) | 501.0K +501.0K (+100.0%) | 0.04% +0.038 pp | 0.01% +0.014 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 66 | METLIFE INVESTMENT MANAGEMENT, LLC | 78.6K +18.2K (+30.3%) | 473.7K +258.4K (+120.0%) | 0.04% +0.008 pp | 0.00% +0.001 pp | USD3.98 +51.5% | 11 qtrs — |
| 67 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 74.9K -19.0K (-20.2%) | 451.5K +116.4K (+34.7%) | 0.03% -0.009 pp | 0.00% +0.000 pp | USD3.55 +69.9% | 20 qtrs — |
| 68 | OXFORD ASSET MANAGEMENT LLP | 74.1K +74.1K (+100.0%) | 446.9K +446.9K (+100.0%) | 0.03% +0.034 pp | 0.18% +0.182 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 69 | JPMORGAN CHASE & CO | 73.1K +9.2K (+14.4%) | 440.5K +212.7K (+93.3%) | 0.03% +0.004 pp | 0.00% +0.000 pp | USD3.37 +78.9% | 32 qtrs — |
| 70 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 71.0K +17.8K (+33.5%) | 428.6K +238.7K (+125.7%) | 0.03% +0.008 pp | 0.00% +0.000 pp | USD4.87 +23.8% | 7 qtrs — |
| 71 | JUMP FINANCIAL, LLC | 70.7K +70.7K (+100.0%) | 426.3K +426.3K (+100.0%) | 0.03% +0.033 pp | 0.01% +0.005 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 72 | PRICE T ROWE ASSOCIATES INC /MD/ | 69.5K +2.1K (+3.1%) | 420.0K +179.0K (+74.3%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD2.98 +102.3% | 21 qtrs — |
| 73 | VIRTU FINANCIAL LLC | 65.6K +65.6K (+100.0%) | 396.0K +396.0K (+100.0%) | 0.03% +0.030 pp | 0.02% +0.015 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 74 | SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 60.6K +— (+0.0%) | 365.6K +149.2K (+68.9%) | 0.03% +0.000 pp | 0.01% +0.004 pp | USD3.07 +96.4% | 5 qtrs — |
| 75 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 59.5K +19.6K (+49.3%) | 358.6K +216.4K (+152.1%) | 0.03% +0.009 pp | 0.01% +0.003 pp | USD3.52 +71.3% | 3 qtrs — |
| 76 | GRAHAM CAPITAL MANAGEMENT, L.P. | 56.0K +2.6K (+4.9%) | 337.8K +147.1K (+77.2%) | 0.03% +0.001 pp | 0.01% +0.005 pp | USD3.68 +63.9% | 2 qtrs — |
| 77 | CREATIVE PLANNING | 55.7K +11.5K (+26.0%) | 336.0K +178.1K (+112.8%) | 0.03% +0.005 pp | 0.00% +0.000 pp | USD3.48 +73.3% | 5 qtrs — |
| 78 | BANK OF NOVA SCOTIA | 51.7K +51.7K (+100.0%) | 311.8K +311.8K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.001 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 79 | SIVIA CAPITAL PARTNERS, LLC | 48.5K +7.0 (+0.0%) | 292.5K +119.4K (+68.9%) | 0.02% +0.000 pp | 0.06% +0.010 pp | USD4.35 +38.6% | 9 qtrs — |
| 80 | DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. | 46.0K +46.0K (+100.0%) | 277.4K +277.4K (+100.0%) | 0.02% +0.021 pp | 0.03% +0.027 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 81 | SG AMERICAS SECURITIES, LLC | 45.5K +45.5K (+100.0%) | 275.0K +275.0K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 82 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 43.5K +5.1K (+13.2%) | 262.6K +125.3K (+91.2%) | 0.02% +0.002 pp | 0.00% +0.000 pp | USD3.64 +65.7% | 11 qtrs — |
| 83 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 41.7K +8.5K (+25.5%) | 251.2K +132.7K (+112.0%) | 0.02% +0.004 pp | 0.00% +0.002 pp | USD3.62 +66.6% | 3 qtrs — |
| 84 | INTECH INVESTMENT MANAGEMENT LLC | 41.0K -5.3K (-11.5%) | 247.0K +81.7K (+49.4%) | 0.02% -0.003 pp | 0.00% +0.001 pp | USD3.65 +65.2% | 6 qtrs — |
| 85 | ENTRYPOINT CAPITAL, LLC | 40.7K -40.9K (-50.1%) | 245.5K -46.0K (-15.8%) | 0.02% -0.019 pp | 0.10% -0.017 pp | USD3.20 +88.4% | 9 qtrs — |
| 86 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 39.6K +37.7K (+1,887.4%) | 239.1K +232.0K (+3,257.0%) | 0.02% +0.017 pp | 0.06% +0.053 pp | USD5.91 +2.0% | 2 qtrs — |
| 87 | SKOPOS LABS, INC. | 36.8K -61.8K (-62.7%) | 233.0K +15.0K (+6.9%) | 0.02% -0.029 pp | 0.01% -0.013 pp | USD2.67 +125.8% | 4 qtrs — |
| 88 | VIRTUS INVESTMENT ADVISERS, INC. | 38.4K -11.9K (-23.6%) | 231.8K +52.1K (+29.0%) | 0.02% -0.006 pp | 0.06% +0.012 pp | USD2.91 +107.2% | 4 qtrs — |
| 89 | JAIN GLOBAL LLC | 37.7K -1.8K (-4.6%) | 227.4K +86.3K (+61.2%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD3.57 +68.9% | 4 qtrs — |
| 90 | NEW YORK STATE COMMON RETIREMENT FUND | 36.6K +22.7K (+163.8%) | 220.4K +171.0K (+345.6%) | 0.02% +0.011 pp | 0.00% +0.000 pp | USD5.23 +15.3% | 11 qtrs — |
| 91 | PROFUND ADVISORS LLC | 35.1K +35.1K (+100.0%) | 211.9K +211.9K (+100.0%) | 0.02% +0.016 pp | 0.01% +0.006 pp | USD6.03 +0.0% | 1 qtrs NEW |
| 92 | PROSHARE ADVISORS LLC | 34.9K +9.1K (+35.5%) | 210.3K +118.4K (+128.8%) | 0.02% +0.004 pp | 0.00% +0.000 pp | USD4.53 +33.1% | 10 qtrs — |
| 93 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 33.9K +— (+0.0%) | 204.6K +83.5K (+68.9%) | 0.02% +0.000 pp | 0.00% +0.001 pp | USD3.18 +89.6% | 5 qtrs — |
| 94 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 33.2K +2.9K (+9.4%) | 199.9K +91.8K (+84.8%) | 0.02% +0.001 pp | 0.02% +0.006 pp | USD4.45 +35.5% | 9 qtrs — |
| 95 | ADVISOR GROUP HOLDINGS, INC. | 32.7K +2.1K (+6.9%) | 197.0K +95.9K (+94.8%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD3.34 +80.5% | 12 qtrs — |
| 96 | BNP PARIBAS ARBITRAGE, SNC | 31.2K +6.1K (+24.1%) | 188.2K +98.4K (+109.5%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD3.80 +58.7% | 11 qtrs — |
| 97 | CITADEL ADVISORS LLC | 29.5K +29.5K (+100.0%) | 177.9K +177.9K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.000 pp | USD6.03 +0.0% | 24 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 85 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | F/M Emerald Life Sciences Innovation ETF LFSC | 3.18% | 2.37M | 0.54% |
| 2 | Virtus Biotech Clinical Trials ETF BBC | 0.71% | 406.2K | 0.65% |
| 3 | Janus Henderson Small Cap Growth Alpha ETF JSML | 0.66% | 2.42M | 0.30% |
| 4 | iShares Micro-Cap ETF IWC | 0.21% | 3.09M | 0.60% |
| 5 | Global X - S&P Biotech ETF CURE.AX | 0.18% | 64.3K | 0.45% |
| 6 | State Street SPDR S&P Biotech ETF XBI | 0.18% | 19.32M | 0.35% |
| 7 | Vanguard U.S. Momentum Factor ETF VFMO | 0.12% | 2.07M | 0.13% |
| 8 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.09% | 393.5K | 0.40% |
| 9 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.09% | 63.5K | 0.19% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.08% | 60.3K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.54
Neutral
Ratio by volume
0.76
Neutral
Buys
7
Sells
13
Shares acquired
368.6K
Shares disposed
485.3K
Cash buys
—
Cash sales
—
Net activity
-116,760
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | Lowrance David L | Officer | M-Exempt | A | Common Stock | 24,850 | 3.35 | 83.2K | 552,550 | D | ↗ |
| 2026-02-16 | McCracken Joseph S | Director | M-Exempt | A | Common Stock | 1,807 | 1.76 | 3.2K | 302,644 | D | ↗ |
| 2025-12-19 | RAMSAY DAVID A | Director | S-Sale | D | Common Stock | 20,000 | 6.06 | 121.2K | 2,533,642 | D | ↗ |
| 2025-12-16 | Pauls Matthew | Director / Officer | G-Gift | D | Common Stock | 128,995 | 0.00 | — | 1,188,050 | D | ↗ |
| 2025-12-16 | Lowrance David L | Officer | G-Gift | D | Common Stock | 32,000 | 0.00 | — | 286,045 | D | ↗ |
| 2025-12-14 | Pauls Matthew | Director / Officer | F-InKind | D | Common Stock | 195,705 | 6.92 | 1.35M | 1,317,045 | D | ↗ |
| 2025-12-14 | McCabe Kathleen R. | Officer | F-InKind | D | Common Stock | 39,350 | 6.92 | 272.3K | 519,232 | D | ↗ |
| 2025-12-14 | Lutz Robert Matthew | Officer | F-InKind | D | Common Stock | 67,760 | 6.92 | 468.9K | 293,977 | D | ↗ |
| 2025-12-14 | Lowrance David L | Officer | F-InKind | D | Common Stock | 62,960 | 6.92 | 435.7K | 318,045 | D | ↗ |
| 2025-12-14 | Erickson Anne | Officer | F-InKind | D | Common Stock | 62,960 | 6.92 | 435.7K | 371,712 | D | ↗ |
| 2025-12-10 | Pauls Matthew | Director / Officer | G-Gift | D | Common Stock | 23,629 | 0.00 | — | 1,512,750 | D | ↗ |
| 2025-12-09 | van Es-Johansson An | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 102,500 | D | ↗ |
| 2025-12-09 | RAMSAY DAVID A | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 2,553,642 | D | ↗ |
| 2025-12-09 | McCracken Joseph S | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 300,837 | D | ↗ |
| 2025-12-09 | Hawkins Richard J | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 161,326 | D | ↗ |
| 2025-12-09 | Elam Nevan C | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 106,887 | D | ↗ |
| 2025-12-04 | Wasfi Yasmine | Officer | F-InKind | D | Common Stock | 21,992 | 6.37 | 140.1K | 168,008 | D | ↗ |
| 2025-12-02 | Elam Nevan C | Director | F-InKind | D | Common Stock | 1,473 | 5.81 | 8.6K | 66,887 | D | ↗ |
| 2025-11-14 | Hawkins Richard J | Director | M-Exempt | A | Common Stock | 5,860 | 1.46 | 8.6K | 121,326 | D | ↗ |
| 2025-10-20 | Wasfi Yasmine | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 190,000 | D | ↗ |
| 2025-10-17 | Wasfi Yasmine | Officer | — | — | Common Stock | 0 | 0.00 | — | 155,000 | D | ↗ |
| 2025-06-20 | Hawkins Richard J | Director | P-Purchase | A | Common Stock | 48,225 | 2.04 | 98.6K | 115,466 | D | ↗ |
| 2025-05-29 | McCracken Joseph S | Director | P-Purchase | A | Common Stock | 10,000 | 2.08 | 20.8K | 260,837 | D | ↗ |
| 2025-03-31 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 150,000 | 2.78 | 416.3K | 2,513,642 | D | ↗ |
| 2025-03-13 | McCabe Kathleen R. | Officer | — | — | Stock Option (Right to Buy) | 34,971 | 1.23 | 43.0K | 0 | D | ↗ |
| 2025-02-13 | Lutz Robert Matthew | Officer | F-InKind | D | Common Stock | 38,263 | 2.83 | 108.3K | 361,737 | D | ↗ |
| 2024-12-16 | Pauls Matthew | Director / Officer | S-Sale | D | Common Stock | 54,702 | 3.31 | 180.8K | 1,536,379 | D | ↗ |
| 2024-12-16 | Lowrance David L | Officer | S-Sale | D | Common Stock | 25,000 | 3.33 | 83.3K | 381,005 | D | ↗ |
| 2024-12-16 | Hawkins Richard J | Director | S-Sale | D | Common Stock | 8,000 | 3.32 | 26.6K | 67,241 | D | ↗ |
| 2024-12-13 | Pauls Matthew | Director / Officer | F-InKind | D | Common Stock | 92,593 | 3.21 | 297.2K | 1,591,081 | D | ↗ |
| 2024-12-13 | Lowrance David L | Officer | F-InKind | D | Common Stock | 24,350 | 3.21 | 78.2K | 406,005 | D | ↗ |
| 2024-12-13 | Erickson Anne | Officer | F-InKind | D | Common Stock | 18,263 | 3.21 | 58.6K | 434,672 | D | ↗ |
| 2024-12-12 | van Es-Johansson An | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 62,500 | D | ↗ |
| 2024-12-12 | RAMSAY DAVID A | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 2,363,642 | D | ↗ |
| 2024-12-12 | Pratt Raymond Dennis | Officer | A-Award | A | Stock Option (Right to Buy) | 280,000 | 3.35 | 938.0K | 280,000 | D | ↗ |
| 2024-12-12 | Pauls Matthew | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 900,000 | 3.35 | 3.02M | 900,000 | D | ↗ |
| 2024-12-12 | Parker Braden C. | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.35 | 134.0K | 40,000 | D | ↗ |
| 2024-12-12 | McCracken Joseph S | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 250,837 | D | ↗ |
| 2024-12-12 | Lutz Robert Matthew | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 400,000 | D | ↗ |
| 2024-12-12 | Lowrance David L | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 3.35 | 1.01M | 300,000 | D | ↗ |
| 2024-12-12 | Hawkins Richard J | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 75,241 | D | ↗ |
| 2024-12-12 | Erickson Anne | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 452,935 | D | ↗ |
| 2024-12-12 | Elam Nevan C | Director | A-Award | A | Common Stock | 40,000 | 0.00 | — | 62,500 | D | ↗ |
| 2024-11-19 | McCracken Joseph S | Director | P-Purchase | A | Common Stock | 20,000 | 2.95 | 59.1K | 210,837 | D | ↗ |
| 2024-11-18 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 100,000 | 2.88 | 287.6K | 2,323,642 | D | ↗ |
| 2024-11-10 | Pratt Raymond Dennis | Officer | F-InKind | D | Common Stock | 49,950 | 3.97 | 198.3K | 260,050 | D | ↗ |
| 2024-10-21 | Erickson Anne | Officer | F-InKind | D | Common Stock | 381 | 3.57 | 1.4K | 352,935 | D | ↗ |
| 2024-09-25 | Parker Braden C. | Officer | A-Award | A | Stock Option (Right to Buy) | 170,000 | 4.15 | 705.5K | 170,000 | D | ↗ |
| 2024-09-24 | Parker Braden C. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-21 | Erickson Anne | Officer | F-InKind | D | Common Stock | 381 | 4.47 | 1.7K | 353,316 | — | ↗ |
| 2024-04-21 | Erickson Anne | Officer | F-InKind | D | Common Stock | 381 | 4.81 | 1.8K | 353,697 | — | ↗ |
| 2024-03-21 | Erickson Anne | Officer | — | D | Stock Option (Right to Buy) | 40,000 | 4.45 | 178.0K | 0 | — | ↗ |
| 2023-12-28 | Pauls Matthew | Director / Officer | G-Gift | D | Common Stock | 19,000 | 0.00 | — | 1,283,674 | — | ↗ |
| 2023-12-28 | Lowrance David L | Officer | S-Sale | D | Common Stock | 10,000 | 4.71 | 47.1K | 342,355 | — | ↗ |
| 2023-12-28 | Elam Nevan C | Director | M-Exempt | A | Common Stock | 12,000 | 1.59 | 19.1K | 76,343 | — | ↗ |
| 2023-12-15 | Lowrance David L | Officer | G-Gift | D | Common Stock | 20,000 | 0.00 | — | 352,355 | — | ↗ |
| 2023-12-14 | van Es-Johansson An | Director | A-Award | A | Common Stock | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2023-12-14 | Sun Ricky | Director | A-Award | A | Common Stock | 22,500 | 0.00 | — | 22,500 | — | ↗ |
| 2023-12-14 | RAMSAY DAVID A | Director | A-Award | A | Common Stock | 22,500 | 0.00 | — | 2,223,642 | — | ↗ |
| 2023-12-14 | Pratt Raymond Dennis | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 4.45 | 178.0K | 40,000 | — | ↗ |
| 2023-12-14 | Pauls Matthew | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 4.45 | 1.00M | 225,000 | — | ↗ |
| 2023-12-14 | McCracken Joseph S | Director | A-Award | A | Common Stock | 22,500 | 0.00 | — | 190,837 | — | ↗ |
| 2023-12-14 | Lutz Robert Matthew | Officer | A-Award | A | Common Stock | 160,000 | 0.00 | — | 300,000 | — | ↗ |
| 2023-12-14 | Lowrance David L | Officer | F-InKind | D | Common Stock | 30,438 | 4.45 | 135.4K | 212,355 | — | ↗ |
| 2023-12-14 | Hawkins Richard J | Director | A-Award | A | Common Stock | 22,500 | 0.00 | — | 35,241 | — | ↗ |
| 2023-12-14 | Elam Nevan C | Director | A-Award | A | Common Stock | 22,500 | 0.00 | — | 62,585 | — | ↗ |
| 2023-12-11 | Hawkins Richard J | Director | M-Exempt | D | Stock Option (Right to Buy) | 10,841 | 0.82 | 8.9K | 0 | — | ↗ |
| 2023-12-11 | Elam Nevan C | Director | M-Exempt | D | Stock Option (Right to Buy) | 10,841 | 0.82 | 8.9K | 0 | — | ↗ |
| 2023-07-17 | Yang Rick | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 3.00 | 1,000.0K | 24,471,264 | — | ↗ |
| 2023-07-17 | Walker Paul Edward | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 3.00 | 1,000.0K | 24,471,264 | — | ↗ |
| 2023-07-17 | SANDELL SCOTT D | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 3.00 | 1,000.0K | 24,471,264 | — | ↗ |
| 2023-07-17 | Mathers Edward T | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 3.00 | 1,000.0K | 24,471,264 | — | ↗ |
| 2023-07-17 | Makhzoumi Mohamad | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 3.00 | 1,000.0K | 24,471,264 | — | ↗ |
| 2023-07-17 | Growth Equity Opportunities 17, LLC | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 3.00 | 1,000.0K | 24,471,264 | — | ↗ |
| 2023-07-17 | Florence Anthony A. Jr. | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 3.00 | 1,000.0K | 24,471,264 | — | ↗ |
| 2023-07-17 | Chang Carmen | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 3.00 | 1,000.0K | 24,471,264 | — | ↗ |
| 2023-07-17 | Behbahani Ali | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 3.00 | 1,000.0K | 24,471,264 | — | ↗ |
| 2023-07-17 | BASKETT FOREST | 10% Owner | P-Purchase | A | Common Stock | 333,333 | 3.00 | 1,000.0K | 24,471,264 | — | ↗ |
| 2023-06-26 | Pratt Raymond Dennis | Officer | P-Purchase | A | Common Stock | 6,500 | 2.93 | 19.0K | 160,000 | — | ↗ |
| 2023-05-26 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 37,124 | 2.63 | 97.6K | 2,201,142 | — | ↗ |
| 2023-05-25 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 12,876 | 2.57 | 33.1K | 2,164,018 | — | ↗ |
| 2023-05-24 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 50,000 | 2.56 | 127.8K | 2,151,142 | — | ↗ |
| 2023-02-24 | Lutz Robert Matthew | Officer | A-Award | A | Stock Option (Right to Buy) | 350,000 | 2.53 | 885.5K | 350,000 | — | ↗ |
| 2023-02-13 | Lutz Robert Matthew | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-30 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 29,000 | 1.55 | 44.8K | 2,101,142 | — | ↗ |
| 2022-12-29 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 7,000 | 1.54 | 10.8K | 2,072,142 | — | ↗ |
| 2022-12-28 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 3,293 | 1.50 | 4.9K | 2,065,142 | — | ↗ |
| 2022-12-23 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 15,707 | 1.44 | 22.7K | 2,061,849 | — | ↗ |
| 2022-12-22 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 41,414 | 1.48 | 61.1K | 2,046,142 | — | ↗ |
| 2022-12-22 | Pratt Raymond Dennis | Officer | P-Purchase | A | Common Stock | 3,500 | 1.54 | 5.4K | 153,500 | — | ↗ |
| 2022-12-20 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 3,586 | 1.48 | 5.3K | 2,004,728 | — | ↗ |
| 2022-12-19 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 40,719 | 1.49 | 60.8K | 1,987,312 | — | ↗ |
| 2022-12-16 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 341 | 1.50 | 511.50 | 1,946,593 | — | ↗ |
| 2022-12-13 | van Es-Johansson An | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-12-13 | Sun Ricky | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-12-13 | RAMSAY DAVID A | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-12-13 | Pauls Matthew | Officer | A-Award | A | Stock Option (Right to Buy) | 700,000 | 0.00 | — | 700,000 | — | ↗ |
| 2022-12-13 | McCracken Joseph S | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-12-13 | Lowrance David L | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-12-13 | Hawkins Richard J | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-12-13 | Elam Nevan C | Director | M-Exempt | D | Stock Option (Right to Buy) | 1,172 | 0.00 | — | 0 | — | ↗ |
| 2022-12-07 | Hawkins Richard J | Director | M-Exempt | A | Common Stock | 1,172 | 0.65 | 761.80 | 1,900 | — | ↗ |
| 2022-11-23 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 4,610 | 1.44 | 6.6K | 1,946,252 | — | ↗ |
| 2022-11-22 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 15,495 | 1.42 | 22.0K | 1,941,642 | — | ↗ |
| 2022-11-21 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 25,005 | 1.42 | 35.5K | 1,926,147 | — | ↗ |
| 2022-11-21 | Pratt Raymond Dennis | Officer | A-Award | A | Stock Option (Right to Buy) | 375,000 | 1.43 | 536.3K | 375,000 | — | ↗ |
| 2022-11-18 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 16,100 | 1.34 | 21.6K | 1,901,142 | — | ↗ |
| 2022-11-17 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 8,900 | 1.27 | 11.3K | 1,885,042 | — | ↗ |
| 2022-11-10 | Pratt Raymond Dennis | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-09-27 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 73,893 | 1.37 | 101.4K | 1,876,142 | — | ↗ |
| 2022-09-26 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 31,107 | 1.38 | 43.1K | 1,802,249 | — | ↗ |
| 2022-09-23 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 30,000 | 1.42 | 42.7K | 1,771,142 | — | ↗ |
| 2022-09-20 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 600 | 1.45 | 870.00 | 1,741,142 | — | ↗ |
| 2022-09-19 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 1,400 | 1.46 | 2.0K | 1,740,542 | — | ↗ |
| 2022-09-16 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 6,000 | 1.44 | 8.7K | 1,739,142 | — | ↗ |
| 2022-09-08 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 29,000 | 1.40 | 40.6K | 1,733,142 | — | ↗ |
| 2022-09-07 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 2,130 | 1.39 | 3.0K | 1,704,142 | — | ↗ |
| 2022-09-06 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 870 | 1.38 | 1.2K | 1,702,012 | — | ↗ |
| 2022-09-01 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 39,768 | 1.42 | 56.5K | 1,701,142 | — | ↗ |
| 2022-08-31 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 39,494 | 1.42 | 56.2K | 1,661,374 | — | ↗ |
| 2022-08-30 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 20,738 | 1.41 | 29.3K | 1,621,880 | — | ↗ |
| 2022-06-21 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 21,094 | 1.38 | 29.1K | 1,562,142 | — | ↗ |
| 2022-06-17 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 39,000 | 1.45 | 56.4K | 1,601,142 | — | ↗ |
| 2021-12-31 | Pauls Matthew | Director / Officer | F-InKind | D | Common Stock | 62,318 | 1.24 | 77.3K | 721,354 | — | ↗ |
| 2021-12-30 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 35,000 | 1.30 | 45.4K | 1,501,142 | — | ↗ |
| 2021-12-29 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 15,000 | 1.25 | 18.7K | 1,466,142 | — | ↗ |
| 2021-12-17 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 25,000 | 1.13 | 28.2K | 1,451,142 | — | ↗ |
| 2021-12-17 | Lowrance David L | Officer | P-Purchase | A | Common Stock | 4,000 | 1.14 | 4.6K | 142,793 | — | ↗ |
| 2021-12-15 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 15,000 | 1.08 | 16.3K | 1,426,142 | — | ↗ |
| 2021-12-14 | van Es-Johansson An | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.11 | 44.4K | 40,000 | — | ↗ |
| 2021-12-14 | Sun Ricky | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.11 | 44.4K | 40,000 | — | ↗ |
| 2021-12-14 | RAMSAY DAVID A | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.11 | 44.4K | 40,000 | — | ↗ |
| 2021-12-14 | Pauls Matthew | Director / Officer | A-Award | A | Common Stock | 400,000 | 0.00 | — | 783,672 | — | ↗ |
| 2021-12-14 | McCracken Joseph S | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.11 | 44.4K | 40,000 | — | ↗ |
| 2021-12-14 | Lowrance David L | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 138,793 | — | ↗ |
| 2021-12-14 | Hawkins Richard J | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.11 | 44.4K | 40,000 | — | ↗ |
| 2021-12-14 | Elam Nevan C | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.11 | 44.4K | 40,000 | — | ↗ |
| 2021-12-14 | Chowdhury Badrul A. | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 300,000 | — | ↗ |
| 2021-12-13 | Hawkins Richard J | Director | M-Exempt | A | Common Stock | 728 | 0.55 | 400.40 | 728 | — | ↗ |
| 2021-12-10 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 35,000 | 1.04 | 36.4K | 1,411,142 | — | ↗ |
| 2021-12-09 | Chowdhury Badrul A. | Officer | P-Purchase | A | Common Stock | 25,000 | 1.05 | 26.3K | 175,000 | — | ↗ |
| 2021-12-08 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 13,157 | 1.05 | 13.8K | 1,376,142 | — | ↗ |
| 2021-12-08 | Pauls Matthew | Director / Officer | P-Purchase | A | Common Stock | 6,500 | 1.06 | 6.9K | 383,672 | — | ↗ |
| 2021-12-07 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 11,843 | 1.05 | 12.4K | 1,362,985 | — | ↗ |
| 2021-12-06 | Elam Nevan C | Director | M-Exempt | A | Common Stock | 1,172 | 0.55 | 644.60 | 28,072 | — | ↗ |
| 2021-12-02 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 21,394 | 1.09 | 23.2K | 1,351,142 | — | ↗ |
| 2021-12-02 | Pauls Matthew | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.10 | 11.0K | 377,172 | — | ↗ |
| 2021-12-01 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 3,606 | 1.08 | 3.9K | 1,329,748 | — | ↗ |
| 2021-11-30 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 16,000 | 1.09 | 17.4K | 1,317,142 | — | ↗ |
| 2021-11-22 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 90,000 | 1.08 | 97.0K | 1,301,142 | — | ↗ |
| 2021-11-19 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 49,800 | 1.07 | 53.2K | 1,211,142 | — | ↗ |
| 2021-11-19 | Pauls Matthew | Director / Officer | P-Purchase | A | Common Stock | 2,150 | 1.07 | 2.3K | 367,172 | — | ↗ |
| 2021-11-18 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 60,200 | 1.08 | 65.1K | 1,161,342 | — | ↗ |
| 2021-11-18 | Pauls Matthew | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.10 | 11.0K | 355,022 | — | ↗ |
| 2021-09-30 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 50,000 | 1.30 | 64.9K | 1,101,142 | — | ↗ |
| 2021-09-29 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 47,500 | 1.28 | 60.7K | 1,051,142 | — | ↗ |
| 2021-09-28 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 39,552 | 1.29 | 50.8K | 1,003,642 | — | ↗ |
| 2021-08-18 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 12,948 | 1.18 | 15.3K | 946,302 | — | ↗ |
| 2021-08-18 | Pauls Matthew | Director / Officer | P-Purchase | A | Common Stock | 11,900 | 1.19 | 14.2K | 345,022 | — | ↗ |
| 2021-08-18 | Elam Nevan C | Director | M-Exempt | D | Stock Option (Right to Buy) | 2,288 | 0.52 | 1.2K | 0 | — | ↗ |
| 2021-08-17 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 66,554 | 1.18 | 78.2K | 933,354 | — | ↗ |
| 2021-08-17 | Pauls Matthew | Director / Officer | P-Purchase | A | Common Stock | 15,000 | 1.18 | 17.7K | 333,122 | — | ↗ |
| 2021-05-21 | Pauls Matthew | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.63 | 16.3K | 318,122 | — | ↗ |
| 2021-05-19 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 5,003 | 1.58 | 7.9K | 866,800 | — | ↗ |
| 2021-05-18 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 50,000 | 1.62 | 81.1K | 861,797 | — | ↗ |
| 2021-05-17 | Chowdhury Badrul A. | Officer | S-Sale | D | Common Stock | 50,000 | 1.56 | 77.9K | 150,000 | — | ↗ |
| 2021-05-15 | Chowdhury Badrul A. | Officer | M-Exempt | D | Restricted Stock Units | 200,000 | 0.00 | — | 0 | — | ↗ |
| 2021-04-19 | Pauls Matthew | Director / Officer | P-Purchase | A | Common Stock | 27,400 | 1.82 | 49.9K | 308,122 | — | ↗ |
| 2021-03-22 | Pauls Matthew | Director / Officer | P-Purchase | A | Common Stock | 24,100 | 2.07 | 49.9K | 280,722 | — | ↗ |
| 2021-03-15 | Yang Rick | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-03-15 | Walker Paul Edward | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-03-15 | Sonsini Peter W. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-03-15 | SANDELL SCOTT D | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-03-15 | RAMSAY DAVID A | Director | P-Purchase | A | Common Stock | 689,655 | 1.45 | 1,000.0K | 811,797 | — | ↗ |
| 2021-03-15 | McCracken Joseph S | Director | P-Purchase | A | Common Stock | 68,965 | 1.45 | 100.0K | 168,337 | — | ↗ |
| 2021-03-15 | Mathers Edward T | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-03-15 | Makhzoumi Mohamad | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-03-15 | MAKOWER JOSHUA | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-03-15 | Lowrance David L | Officer | P-Purchase | A | Common Stock | 13,793 | 1.45 | 20.0K | 13,793 | — | ↗ |
| 2021-03-15 | Landsman Liza | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-03-15 | Growth Equity Opportunities 17, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-03-15 | Florence Anthony A. Jr. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-03-15 | Chang Carmen | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-03-15 | Behbahani Ali | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-03-15 | BASKETT FOREST | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 24,137,931 | — | ↗ |
| 2021-02-22 | Pauls Matthew | Officer | P-Purchase | A | Common Stock | 28,700 | 1.74 | 50.0K | 256,622 | — | ↗ |
| 2020-12-16 | van Es-Johansson An | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.23 | 49.2K | 40,000 | — | ↗ |
| 2020-12-16 | Sun Ricky | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.23 | 49.2K | 40,000 | — | ↗ |
| 2020-12-16 | RAMSAY DAVID A | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.23 | 49.2K | 40,000 | — | ↗ |
| 2020-12-16 | Pauls Matthew | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.23 | 615.0K | 500,000 | — | ↗ |
| 2020-12-16 | McCracken Joseph S | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.23 | 49.2K | 40,000 | — | ↗ |
| 2020-12-16 | Lowrance David L | Officer | A-Award | A | Stock Option (Right to Buy) | 260,000 | 1.23 | 319.8K | 260,000 | — | ↗ |
| 2020-12-16 | Hawkins Richard J | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.23 | 49.2K | 40,000 | — | ↗ |
| 2020-12-16 | Elam Nevan C | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.23 | 49.2K | 40,000 | — | ↗ |
| 2020-12-16 | Chowdhury Badrul A. | Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 1.23 | 338.3K | 275,000 | — | ↗ |
| 2020-12-15 | Elam Nevan C | Director | M-Exempt | A | Common Stock | 2,930 | 0.52 | 1.5K | 24,612 | — | ↗ |
| 2020-09-15 | Pauls Matthew | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 898,639 | 1.32 | 1.19M | 898,639 | — | ↗ |
| 2020-03-10 | Sun Ricky | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 2.55 | 30.6K | 12,000 | — | ↗ |
| 2019-12-24 | Sun Ricky | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-20 | van Es-Johansson An | Director | A-Award | A | Stock Option (Right to Buy) | 12,000 | 1.59 | 19.1K | 12,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
204.92M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Matthew Pauls Chief Executive Officer | 660.0K | — | 3.87M | — | 297.0K | 18.0K | 4.85M | 79.88% | ↗ |
| 2 | 2025 | Yasmine Wasfi Chief Medical Officer | 476.7K | — | 1.69M | 246.7K | 186.9K | 18.0K | 2.62M | 73.99% | ↗ |
| 3 | 2025 | David Lowrance Chief Financial & Administrative Officer & Secretary | 471.0K | — | 1.61M | — | 176.6K | 18.0K | 2.28M | 70.78% | ↗ |
| 4 | 2025 | Robert Lutz Chief Operating Officer | 471.0K | — | 1.61M | — | 176.6K | 18.0K | 2.28M | 70.78% | ↗ |
| 5 | 2024 | Matthew Pauls Chief Executive Officer | 620.0K | 31.0K | 1.34M | 2.59M | 310.0K | 18.0K | 4.91M | 80.07% | ↗ |
| 6 | 2024 | David Lowrance Chief Financial & Administrative Officer & Secretary | 455.1K | 18.2K | 335.0K | 864.3K | 182.0K | 18.0K | 1.87M | 64.05% | ↗ |
| 7 | 2024 | Robert Lutz Chief Operating Officer | 454.5K | 18.2K | 335.0K | 864.3K | 181.8K | 18.0K | 1.87M | 64.07% | ↗ |
| 8 | 2023 | Matthew Pauls Chief Executive Officer | 595.0K | 59.5K | 2.00M | 787.2K | 297.5K | 18.0K | 3.76M | 74.20% | ↗ |
| 9 | 2023 | Robert Lutz Chief Operating Officer | 387.3K | 143.4K | 1.07M | 874.5K | 174.8K | 18.0K | 2.66M | 72.84% | ↗ |
| 10 | 2023 | David Lowrance Chief Financial & Administrative Officer & Secretary | 437.6K | 32.8K | 712.0K | 140.0K | 175.0K | 22.0K | 1.52M | 56.07% | ↗ |
| 11 | 2022 | Matthew Pauls Chief Executive Officer | 580.0K | — | 490.8K | 810.3K | 290.0K | 24.5K | 2.20M | 59.26% | ↗ |
| 12 | 2022 | David Lowrance Chief Financial & Administrative Officer & Secretary | 416.7K | 8.3K | 151.0K | 289.4K | 166.7K | 22.0K | 1.05M | 41.78% | ↗ |
| 13 | 2022 | Raymond Pratt Chief Medical Officer | 65.6K | — | 214.5K | 392.3K | 26.3K | — | 698.7K | 86.85% | ↗ |
| 14 | 2021 | Matthew Pauls Chief Executive Officer | 560.0K | — | 444.0K | 285.5K | 329.0K | 21.8K | 1.64M | 44.47% | ↗ |
| 15 | 2021 | Badrul Chowdhury Chief Medical Officer | 540.8K | — | 138.8K | 81.6K | 258.2K | 18.0K | 1.04M | 21.24% | ↗ |
| 16 | 2021 | David Lowrance Chief Financial Officer & Secretary | 395.0K | — | 138.8K | 81.6K | 188.6K | 22.0K | 825.9K | 26.68% | ↗ |
| 17 | 2021 | David Lowrance Chief Financial & Administrative Officer & Secretary | 395.0K | — | 138.8K | 81.6K | 188.6K | 22.0K | 825.9K | 26.68% | ↗ |
| 18 | 2020 | Matthew Pauls Chief Executive Officer | 169.7K | — | 300.0K | 1.35M | 74.6K | 39.8K | 1.94M | 85.33% | ↗ |
| 19 | 2020 | Robert Neville Former Chief Executive Officer | 382.6K | — | — | 122.3K | — | 823.2K | 1.33M | 9.21% | ↗ |
| 20 | 2020 | Taneli Jouhikainen Former Chief Operating Officer; Chief Business Officer & President | 382.6K | — | — | 83.0K | — | 814.8K | 1.28M | 6.49% | ↗ |
| 21 | 2020 | Badrul Chowdhury Chief Medical Officer | 525.0K | — | — | 259.4K | 223.5K | 18.0K | 1.03M | 25.29% | ↗ |
| 22 | 2020 | David Lowrance Chief Financial Officer & Secretary | 379.6K | — | — | 245.3K | 161.6K | 22.0K | 808.5K | 30.34% | ↗ |
| 23 | 2019 | Robert Neville Chief Executive Officer | 546.0K | — | — | 240.9K | 238.9K | 22.0K | 1.05M | 22.99% | ↗ |
| 24 | 2019 | Robert Neville Former Chief Executive Officer | 546.0K | — | — | 240.9K | 238.9K | 22.0K | 1.05M | 22.99% | ↗ |
| 25 | 2019 | Taneli Jouhikainen Chief Operating Officer & President | 546.0K | — | — | 240.9K | 201.3K | 22.0K | 1.01M | 23.85% | ↗ |
| 26 | 2019 | Taneli Jouhikainen Former Chief Operating Officer; Chief Business Officer & President | 546.0K | — | — | 240.9K | 201.3K | 22.0K | 1.01M | 23.85% | ↗ |
| 27 | 2019 | David Lowrance Chief Financial Officer & Secretary | 379.6K | — | — | 180.7K | 116.7K | 22.0K | 699.0K | 25.85% | ↗ |
| 28 | 2019 | Badrul Chowdhury Chief Medical Officer | 65.6K | 150.0K | 202.0K | 227.9K | 50.0K | — | 695.5K | 61.81% | ↗ |
| 29 | 2019 | Matthew Pauls Chief Executive Officer | — | — | — | 14.4K | — | 49.4K | 63.8K | 22.60% | ↗ |
| 30 | 2018 | Robert Neville Chief Executive Officer | 525.0K | — | — | 3.34M | 225.8K | 22.0K | 4.12M | 81.22% | ↗ |
| 31 | 2018 | Taneli Jouhikainen Chief Operating Officer & President | 525.0K | — | — | 3.13M | 204.1K | 22.0K | 3.88M | 80.67% | ↗ |
| 32 | 2018 | Dave Lowrance Chief Financial Officer & Secretary | 365.0K | — | — | 1.67M | 116.9K | 22.0K | 2.18M | 76.84% | ↗ |
| 33 | 2018 | David Lowrance Chief Financial Officer & Secretary | 365.0K | — | — | 1.67M | 116.9K | 22.0K | 2.18M | 76.84% | ↗ |
| 34 | 2017 | Brian M. Culley Former Chief Executive Officer | 128.6K | 53.6K | 350.5K | — | — | 1.05M | 1.58M | 22.15% | ↗ |
| 35 | 2017 | Edwin Parsley Former Chief Medical Office & Senior Vice President | 101.0K | 31.9K | 132.4K | — | — | 475.3K | 740.6K | 17.88% | ↗ |
| 36 | 2017 | Brandi L. Roberts Former Chief Financial Officer & Senior Vice President | 100.8K | 27.3K | 131.7K | — | — | 353.3K | 613.1K | 21.48% | ↗ |
| 37 | 2017 | Robert Neville Chief Executive Officer | 210.9K | 276.8K | — | — | 90.8K | 21.8K | 600.2K | 0.00% | ↗ |
| 38 | 2017 | Taneli Jouhikainen Chief Operating Officer & President | 210.9K | 276.8K | — | — | 90.8K | 21.8K | 600.2K | 0.00% | ↗ |
| 39 | 2017 | Shana Hood Former General Counsel, Vice President & Secretary | 88.8K | 24.5K | 67.1K | — | — | 301.8K | 482.2K | 13.92% | ↗ |
| 40 | 2017 | Dave Lowrance Chief Financial Officer & Secretary | 204.3K | 88.1K | — | — | 90.8K | 6.0K | 389.1K | 0.00% | ↗ |
| 41 | 2016 | Gregory D. Gorgas Former Senior Vice President, Commercial | 297.8K | — | — | 235.4K | — | 322.5K | 855.8K | 27.51% | ↗ |
| 42 | 2016 | Brian M. Culley Former Chief Executive Officer | 428.6K | — | — | 359.2K | — | 17.2K | 804.9K | 44.62% | ↗ |
| 43 | 2016 | R. Martin Emanuele Former Senior Vice President, Development | 266.8K | — | — | 180.4K | — | 337.0K | 784.3K | 23.00% | ↗ |
| 44 | 2016 | Edwin Parsley Former Chief Medical Office & Senior Vice President | 364.6K | — | — | 167.6K | — | 19.4K | 551.6K | 30.39% | ↗ |
| 45 | 2016 | Edwin L. Parsley Former Chief Medical Officer & Senior Vice President | 364.6K | — | — | 167.6K | — | 19.4K | 551.6K | 30.39% | ↗ |
| 46 | 2016 | Brandi L. Roberts Former Chief Financial Officer & Senior Vice President | 312.0K | — | — | 167.6K | — | 16.6K | 496.2K | 33.78% | ↗ |
| 47 | 2016 | Shana Hood Former General Counsel, Vice President & Secretary | 280.0K | — | — | 119.7K | — | 16.5K | 416.2K | 28.76% | ↗ |
| 48 | 2015 | Brian M. Culley Chief Executive Officer | 419.2K | — | — | 1.29M | 171.9K | 17.5K | 1.89M | 67.88% | ↗ |
| 49 | 2015 | Brian M. Culley Former Chief Executive Officer | 419.2K | — | — | 1.29M | 171.9K | 17.5K | 1.89M | 67.88% | ↗ |
| 50 | 2015 | Patrick L. Keran Former President & Chief Operating Officer | 66.8K | — | — | 1.04M | — | 547.3K | 1.65M | 62.87% | ↗ |
| 51 | 2015 | Edwin Parsley Former Chief Medical Office & Senior Vice President | 353.1K | — | — | 637.3K | 101.3K | 65.9K | 1.16M | 55.05% | ↗ |
| 52 | 2015 | Edwin L. Parsley Former Chief Medical Officer & Senior Vice President | 353.1K | — | — | 637.3K | 101.3K | 65.9K | 1.16M | 55.05% | ↗ |
| 53 | 2015 | Edwin L. Parsley Chief Medical Officer & Senior Vice President | 353.1K | — | — | 637.3K | 101.3K | 65.9K | 1.16M | 55.05% | ↗ |
| 54 | 2015 | Brandi L. Roberts Chief Financial Officer & Senior Vice President | 300.0K | — | — | 494.4K | 73.8K | 17.3K | 885.5K | 55.83% | ↗ |
| 55 | 2015 | Brandi L. Roberts Former Chief Financial Officer & Senior Vice President | 300.0K | — | — | 494.4K | 73.8K | 17.3K | 885.5K | 55.83% | ↗ |
| 56 | 2015 | R. Martin Emanuele Former Senior Vice President, Development | 310.5K | — | — | 336.2K | 76.4K | 21.2K | 744.2K | 45.17% | ↗ |
| 57 | 2014 | Brian M. Culley Chief Executive Officer | 405.0K | — | — | 863.0K | 189.6K | 16.4K | 1.47M | 58.55% | ↗ |
| 58 | 2014 | Brian M. Culley Former Chief Executive Officer | 405.0K | — | — | 863.0K | 189.6K | 16.4K | 1.47M | 58.55% | ↗ |
| 59 | 2014 | Brian M. Culley Chief Executive Officer | 405.0K | — | — | 863.0K | 189.6K | 16.4K | 1.47M | 58.55% | ↗ |
| 60 | 2014 | Patrick L. Keran Former President and Chief Operating Officer | 399.5K | — | — | 863.0K | 189.6K | 16.4K | 1.47M | 58.77% | ↗ |
| 61 | 2014 | Patrick L. Keran Former President & Chief Operating Officer | 399.5K | — | — | 863.0K | 189.6K | 16.4K | 1.47M | 58.77% | ↗ |
| 62 | 2014 | Santosh J. Vetticaden Former Chief Medical Officer and Senior Vice President | 266.0K | — | — | 404.5K | — | 327.6K | 998.1K | 40.53% | ↗ |
| 63 | 2014 | R. Martin Emanuele Former Senior Vice President, Development | 300.0K | — | — | 201.0K | 84.3K | 20.1K | 605.4K | 33.21% | ↗ |
| 64 | 2014 | 2014 Summary Compensation Table Name and Principal Position | 2.0K | 2.0K | 2.0K | 2.0K | 2.0K | 2.0K | 2.0K | 200.00% | ↗ |
| 65 | 2013 | Brian M. Culley Chief Executive Officer | 393.8K | — | — | 437.7K | 192.0K | 16.1K | 1.04M | 42.10% | ↗ |
| 66 | 2013 | Patrick L. Keran President and Chief Operating Officer | 388.8K | — | — | 437.7K | 192.0K | 16.1K | 1.03M | 42.31% | ↗ |
| 67 | 2013 | Patrick L. Keran Former President and Chief Operating Officer | 388.8K | — | — | 437.7K | 192.0K | 16.1K | 1.03M | 42.31% | ↗ |
| 68 | 2013 | Santosh J. Vetticaden Former Chief Medical Officer and Senior Vice President | 350.0K | — | — | 50.3K | 104.9K | 17.1K | 522.3K | 9.63% | ↗ |
| 69 | 2013 | Santosh J. Vetticaden Chief Medical Officer and Senior Vice President | 350.0K | — | — | 50.3K | 104.9K | 17.1K | 522.3K | 9.63% | ↗ |
| 70 | 2012 | Santosh J. Vetticaden Chief Medical Officer and Senior Vice President | 113.8K | 100.0K | — | 370.9K | 39.6K | 7.3K | 631.5K | 58.73% | ↗ |
| 71 | 2012 | Santosh J. Vetticaden Chief Medical Officer and Senior Vice President | 113.8K | 100.0K | — | 370.9K | 39.6K | 7.3K | 631.5K | 58.73% | ↗ |
| 72 | 2012 | Brian M. Culley Chief Executive Officer | 375.0K | — | — | — | 156.2K | 16.7K | 547.9K | 0.00% | ↗ |
| 73 | 2012 | Patrick L. Keran President and Chief Operating Officer | 370.0K | — | — | — | 156.2K | 15.8K | 542.0K | 0.00% | ↗ |
| 74 | 2011 | Brian M. Culley Chief Executive Officer | 360.8K | — | — | 1.16M | 131.3K | 17.6K | 1.67M | 69.55% | ↗ |
| 75 | 2011 | Patrick L. Keran President and Chief Operating Officer | 344.0K | — | — | 1.16M | 131.3K | 17.7K | 1.66M | 70.26% | ↗ |
| 76 | 2011 | Gregory D. Gorgas | 104.2K | — | — | 395.2K | 23.6K | 234.3K | 775.3K | 50.97% | ↗ |
| 77 | 2010 | Brian M. Culley Chief Executive Officer | 315.0K | — | — | 457.4K | 112.5K | 19.5K | 904.4K | 50.57% | ↗ |
| 78 | 2010 | Patrick L. Keran President and Chief Operating Officer | 289.0K | — | — | 457.4K | 112.5K | 19.5K | 878.4K | 52.07% | ↗ |
| 79 | 2009 | Brian M. Culley Chief Executive Officer | 316.8K | — | — | — | — | — | 758.7K | 0.00% | ↗ |
| 80 | 2009 | Patrick L. Keran President and Chief Operating Officer | 290.8K | — | — | — | — | — | 737.8K | 0.00% | ↗ |
| 81 | 2009 | Michele L. Yelmene Former Vice President, Regulatory | 102.8K | — | — | — | — | — | 197.7K | 0.00% | ↗ |
| 82 | 2008 | Evan M. Levine Former Chief Executive Officer | 381.6K | — | — | — | — | 493.7K | 875.3K | 0.00% | ↗ |
| 83 | 2008 | Joan M. Robbins Former Chief Scientific Officer | 224.7K | — | — | 182.0K | — | 86.1K | 492.8K | 36.93% | ↗ |
| 84 | 2008 | Brian M. Culley Chief Business Officer | 262.5K | — | — | 183.5K | — | 14.0K | 460.0K | 39.89% | ↗ |
| 85 | 2008 | Gregory P. Hanson Former Chief Financial Officer | 67.3K | — | — | 38.2K | — | 341.5K | 447.0K | 8.54% | ↗ |
| 86 | 2008 | Mark N.K. Bagnall | 258.5K | — | — | 37.6K | — | 97.8K | 393.9K | 9.55% | ↗ |
| 87 | 2008 | Brian M. Culley Chief Executive Officer | 262.5K | — | — | — | — | — | 379.1K | 0.00% | ↗ |
| 88 | 2008 | Patrick Keran | 231.0K | — | — | 121.7K | — | 13.8K | 366.5K | 33.21% | ↗ |
| 89 | 2008 | Patrick L. Keran President and | 231.0K | — | — | — | — | — | 347.4K | 0.00% | ↗ |
| 90 | 2008 | Michele L. Yelmene Former Vice President, Regulatory | — | — | — | — | — | — | — | — | ↗ |
| 91 | 2007 | Evan M. Levine Former Chief Executive Officer | 450.0K | 200.0K | — | — | — | 9.2K | 659.2K | 0.00% | ↗ |
| 92 | 2007 | Evan M. Levine Chief Executive Officer | 450.0K | 200.0K | — | — | — | 8.4K | 658.4K | 0.00% | ↗ |
| 93 | 2007 | James A. Merritt President Chief Medical Officer | 362.5K | — | — | — | — | 10.0K | 593.1K | 0.00% | ↗ |
| 94 | 2007 | Brian M. Culley Chief Business Officer | 250.0K | — | — | 235.9K | — | 9.2K | 495.0K | 47.65% | ↗ |
| 95 | 2007 | Joan M. Robbins Chief Scientific Officer | 265.0K | — | — | 192.1K | — | 9.8K | 466.9K | 41.15% | ↗ |
| 96 | 2007 | Joan M. Robbins Former Chief Scientific Officer | 265.0K | — | — | 192.1K | — | 9.3K | 466.4K | 41.19% | ↗ |
| 97 | 2007 | Gregory P. Hanson Former Chief Financial Officer | 250.0K | — | — | 149.5K | — | 10.2K | 409.7K | 36.49% | ↗ |
| 98 | 2007 | Gregory P. Hanson Chief Financial Officer | 250.0K | — | — | 149.5K | — | 9.7K | 409.2K | 36.53% | ↗ |
| 99 | 2006 | Carrie E. Carlander, former Chief Financial Officer | 138.5K | — | 196.7K | 170.4K | — | 139.5K | 645.0K | 56.91% | ↗ |
| 100 | 2006 | James A. Merritt, President Chief Medical Officer | 102.5K | 37.5K | 24.1K | 66.5K | — | 271.2K | 501.7K | 18.04% | ↗ |
| 101 | 2006 | James A. Merritt President Chief Medical Officer | 102.5K | 37.5K | 24.1K | — | — | 271.2K | 501.7K | 4.79% | ↗ |
| 102 | 2006 | Joan M. Robbins Chief Scientific Officer | 250.0K | — | — | 144.6K | — | 6.4K | 401.0K | 36.07% | ↗ |
| 103 | 2006 | Joan M. Robbins, Chief Scientific Officer | 250.0K | — | — | 144.6K | — | 6.4K | 401.0K | 36.07% | ↗ |
| 104 | 2006 | Evan M. Levine, Chief Executive Officer | 250.0K | 100.0K | — | — | — | 10.2K | 360.2K | 0.00% | ↗ |
| 105 | 2006 | Evan M. Levine Chief Executive Officer | 250.0K | 100.0K | — | — | — | 10.2K | 360.2K | 0.00% | ↗ |
| 106 | 2006 | Brian M. Culley Chief Business Officer | 200.0K | — | — | 147.6K | — | 8.2K | 355.8K | 41.48% | ↗ |
| 107 | 2006 | Brian M. Culley, Chief Business Officer | 200.0K | — | — | 147.6K | — | 8.2K | 355.8K | 41.48% | ↗ |
| 108 | 2006 | Robert A. Daniel, former acting Chief Financial Officer | 130.9K | — | — | 81.0K | — | 36.00 | 211.8K | 38.21% | ↗ |
| 109 | 2006 | Gregory P. Hanson Chief Financial Officer | 7.7K | — | — | 12.5K | — | — | 20.2K | 61.83% | ↗ |
| 110 | 2006 | Gregory P. Hanson, Chief Financial Officer | 7.7K | — | — | 12.5K | — | — | 20.2K | 61.83% | ↗ |
| 111 | 2005 | Evan Levine Chief Executive Officer and President | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 112 | 2005 | Joan M. Robbins Executive Vice President and Chief Science Officer | 230.0K | — | — | — | — | — | 230.0K | 0.00% | ↗ |
| 113 | 2005 | Carrie E. Carlander Chief Financial Officer, Senior Vice President, Finance, Treasurer and Secretary | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
| 114 | 2005 | Brian M. Culley Senior Vice President, Business Development | 170.0K | — | — | — | — | — | 170.0K | 0.00% | ↗ |
| 115 | 2005 | Mark J. Cantwell Vice President, Research Development | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 116 | 2004 | Evan Levine Chief Executive Officer and President | 210.0K | — | — | — | — | — | 210.0K | 0.00% | ↗ |
| 117 | 2004 | Joan M. Robbins Executive Vice President and Chief Science Officer | 182.5K | — | — | — | — | — | 182.5K | 0.00% | ↗ |
| 118 | 2004 | Carrie E. Carlander Chief Financial Officer, Vice President, Finance, and Treasurer | 157.8K | — | — | — | — | — | 157.8K | 0.00% | ↗ |
| 119 | 2004 | Brian M. Culley Vice President, Business Development | 127.5K | — | — | — | — | — | 127.5K | 0.00% | ↗ |
| 120 | 2004 | Mark J. Cantwell Vice President, Research Development | 90.0K | — | — | — | — | — | 90.0K | 0.00% | ↗ |
| 121 | 2004 | Nicholas J. Virca Chief Executive Officer and President | 85.0K | — | — | — | — | — | 85.0K | 0.00% | ↗ |
| 122 | 2004 | Carrie E. Carlander Chief Financial Officer, Senior Vice President, Finance, Treasurer and Secretary | 22.5K | — | — | — | — | — | 22.5K | 0.00% | ↗ |
| 123 | 2004 | Brian M. Culley Senior Vice President, Business Development | 14.2K | — | — | — | — | — | 14.2K | 0.00% | ↗ |
| 124 | 2004 | Evan Levine Chief Executive Officer, President, Chief Operating Officer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 125 | 2004 | Joan M. Robbins Chief Technical Officer | — | — | — | — | — | — | — | — | ↗ |
| 126 | 2004 | Cellia Habita Senior Vice President, Clinical Operations | — | — | — | 100.0K | — | — | — | — | ↗ |
| 127 | 2003 | Evan Levine Chief Executive Officer, President, Chief Operating Officer and Secretary | 210.0K | — | — | 250.0K | — | — | 210.0K | 119.05% | ↗ |
| 128 | 2003 | Cellia Habita Senior Vice President, Clinical Operations | 182.5K | — | — | — | — | — | 182.5K | 0.00% | ↗ |
| 129 | 2003 | Joan M. Robbins Chief Technical Officer | 155.0K | — | — | 300.0K | — | — | 155.0K | 193.50% | ↗ |
| 130 | 2003 | Joan M. Robbins Executive Vice President and Chief Science Officer | 127.5K | — | — | — | — | — | 127.5K | 0.00% | ↗ |
| 131 | 2003 | Evan Levine Chief Executive Officer and President | 85.0K | — | — | — | — | — | 85.0K | 0.00% | ↗ |
| 132 | 2003 | Nicholas J. Virca Chief Executive Officer and President | — | 15.0K | — | — | — | — | 15.0K | 0.00% | ↗ |
| 133 | 2003 | Mark J. Cantwell Vice President, Research Development | 15.0K | — | — | — | — | — | 15.0K | 0.00% | ↗ |
| 134 | 2003 | Carrie E. Carlander Chief Financial Officer, Senior Vice President, Finance, Treasurer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 135 | 2003 | Brian M. Culley Senior Vice President, Business Development | — | — | — | — | — | — | — | — | ↗ |
| 136 | 2003 | Brian M. Culley Vice President, Business Development | — | — | — | — | — | — | — | — | ↗ |
| 137 | 2003 | Carrie E. Carlander Chief Financial Officer, Vice President, Finance, and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 138 | 2002 | Carrie E. Carlander Chief Financial Officer, Vice President, Finance, and Treasurer | 120.2K | — | — | — | — | — | 120.2K | 0.00% | ↗ |
| 139 | 2002 | Joan M. Robbins Chief Technical Officer | — | — | — | — | — | — | — | — | ↗ |
| 140 | 2002 | Nicholas J. Virca Chief Executive Officer and President | — | — | — | 1.67M | — | — | — | — | ↗ |
| 141 | 2002 | Brian M. Culley Vice President, Business Development | — | — | — | — | — | — | — | — | ↗ |
| 142 | 2002 | Evan Levine Chief Executive Officer, President, Chief Operating Officer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 143 | 2002 | Cellia Habita Senior Vice President, Clinical Operations | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Matthew Pauls | Chairman & Chief Executive Officer | 975.0K | male |
| Yasmine Wasfi | Chief Medical Officer | 681.6K | — |
| Robert Lutz | Chief Operating Officer | 665.6K | male |
| David L. Lowrance | Chief Financial & Administrative Officer and Secretary | 665.6K | male |
| Anne Erickson | Chief Business & Corporate Affairs Officer | — | female |
| Siddharth J. Advant | Executive Vice President of Global Technical Operations | — | — |
| Kate McCabe | Chief Legal Officer | — | female |
| Brian Maurer | Head of Clinical Operations | — | — |
| Brian Robinson | Executive Vice President of Global Medical Affairs | — | — |
| Charles LaPree | Executive Vice President & Head of Global Regulatory Affairs | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SVRA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
